Renal vein thrombosis: Difference between revisions

Jump to navigation Jump to search
Line 87: Line 87:
}}</ref>   
}}</ref>   
* Thrombus emboli
* Thrombus emboli
* Systemic lupus erythematosis
* [[Antiphospholipid antibody syndrome]]
* [[Antiphospholipid antibody syndrome]]
* [[Behçet's syndrome]]
* [[Behçet's syndrome]]

Revision as of 15:34, 1 June 2018

Renal vein thrombosis
Transplant with Renal Vein Thrombosis: Gross; natural color, opened kidney and vein.
Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology
ICD-10 I82.3
ICD-9 453.3
DiseasesDB 11359
MedlinePlus 000513

Template:Search infobox

For patient information page, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Saeedeh Kowsarnia M.D.[2]

Overview

Renal vein thrombosis (RVT) is the formation of a clot or thrombus obstructing the renal vein.

Classification

  • Renal vein thrombosis is classified based on the onset of the symptoms:
Renal vein thrombosis
Onset Presentation Etiology
Acute
  • Renal infarction
  • Renal failure
  • Proteinuria (rarely)
  • Trauma
  • Dehydration
  • Hypercoagulable state
Chronic
  • Asymptomatic
  • Pulmonary embolism
  • Worsening proteinuria or renal function
  • Nephrotic syndrome
  • Malignancy
  • Based on the location RVT may be unilateral or bilateral.

Pathophysiology

A hypercoagulable state or mechanical compression of the renal vein is often present in those patients with renal vein thrombosis. This can be due to malignancy or it can be due to the nephrotic syndrome. In nephrotic syndrome there is an excessive urinary protein loss which is in turn associated with decreased antithrombin III. It is unclear why the renal vein is susceptible to thrombosis in patients with nephrotic syndrome.

Causes

Causes

Epidemiology and Demographics

Malignancy especially renal cell carcinoma is the most common etiology consists of

Prevalence of renal vein thrombosis in nephrotic syndrome is 5 to 60% [4] .Membranous nephropathy is responsible for 20 to 60 % of the cases which makes it the most common cause of renal vain thrombosis among nephrotic syndromes. Other etiologies like minimal change disease, membranoproliferative glomerulonephritis, and focal segmental glomerulosclerosis cause 10 to 50 % of the cases.

Risk Factors

  • Nephrotic syndrome [5]
    • Those with membranous nephropathy and protein excretion above 10 g/day
    • Serum albumin concentration below 2 g/dL (20 g/L))
    • The risk of thromboembolic event is greater with lower serum albumin

Screening

  • Screening should be done for patients
    • Who present with signs of renal infarct
    • Who has chronic bilateral RVT with worsening creatinine and proteinuria to see weather anticoagulation is necessary
  • There is no beneficial evidence regarding screening in patients with nephrotic syndrome and overt embolism.

Diagnosis

Signs and Symptoms

  • Asymptomatic
  • Renal infarct [6]   
    • Flank pain
    • Nausea and vomiting
    • Fever
    • Microscopic or gross hematuria
    • Marked elevation in serum lactate dehydrogenase (without change in transaminases)
    • Increase in renal size on radiographic study
  • Renal failure (bilateral RVT)
  • Proteinuria (rarely)
  • Pulmonary embolism

Imaging

  • Renal venography: gold standard test for RVT diagnosis
  • Spiral computed tomography (CT) with contrast
  • Magnetic resonance imaging (MRI)
  • Doppler ultrasonography

Treatment

Therapy in RVT:

Classification Condition
Fibrinolytic therapy and catheter thrombectomy
  • Systemic: not recommended, ↑ risk of bleeding
  • Local:
    • For acute RVT
    • Patients with nephrotic syndrome will benefit the most
Surgery
  • Acute bilateral RVT
  • Acute renal failure who cannot be treated with percutaneous thrombectomy and/or thrombolysis
Anticoagulation therapy

Prophylaxy:

  • Nephrotic syndrome:
    • With additional risk factors: Prior idiopathic thromboembolic event, immobilization, severe heart failure, morbid obesity, surgery ( abdominal, orthopedic or gynecologic), genetic thrombophilia (factor V Leiden variant), atrial fibrillation
    • With serum albumin concentration < 2.0 g/dL (20 g/L) and a low to moderate bleeding risk(calculate the risk of bleeding with ATRIA score)
  • Membranous nephropathy:
    • With serum albumin < 3.0 g/dL (30 g/L) and low risk for bleeding
    • With serum albumin < 2.0 g/dL (20 g/L) and intermediate risk of bleeding (ATRIA score)
  • Regimen: Warfarin, heparin, or aspirin.

Asymptomatic RVT

Thrombotic events: DVT or PE with or without RVT in high risk cases and acute RVT with or without other thrombotic events (DVT, PE)

  • Inferior vena cava filters: Suprarenal IVC filters are used in patients with pulmonary embolism and documented renal vein thrombosis with contraindications to anticoagulation
  • Regimen: Unfractionated or low-molecular-weight heparin is the initial drug and then warfarin. Treatment is given for a minimum of 6 to 12 months and continues as long as the patient remains nephrotic.

† ATRIA risk score [7]= Anticoagulation and Risk Factors in Atrial Fibrillation

Related Chapters

References

  1. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016
  2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:68 ISBN 140510368X
  3. Shinji Onda, Hiroaki Shiba, Yuki Takano, Kenei Furukawa, Taigo Hata & Katsuhiko Yanaga (2018). "Renal Infarction during Anticoagulant Therapy after Living Donor Liver Transplantation". Case reports in gastroenterology. 12 (1): 165–169. doi:10.1159/000488526. PMID 29805361. Unknown parameter |month= ignored (help)
  4. Rajni Singhal & K. Scott Brimble (2006). "Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management". Thrombosis research. 118 (3): 397–407. doi:10.1016/j.thromres.2005.03.030. PMID 15990160.
  5. T. J. Rabelink, J. J. Zwaginga, H. A. Koomans & J. J. Sixma (1994). "Thrombosis and hemostasis in renal disease". Kidney international. 46 (2): 287–296. PMID 7967339. Unknown parameter |month= ignored (help)
  6. F. Llach (1985). "Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome". Kidney international. 28 (3): 429–439. PMID 3906225. Unknown parameter |month= ignored (help)
  7. Margaret C. Fang, Alan S. Go, Yuchiao Chang, Leila H. Borowsky, Niela K. Pomernacki, Natalia Udaltsova & Daniel E. Singer (2011). "A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study". Journal of the American College of Cardiology. 58 (4): 395–401. doi:10.1016/j.jacc.2011.03.031. PMID 21757117. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources